Viatris Inc
NASDAQ:VTRS
Intrinsic Value
Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. [ Read More ]
The intrinsic value of one VTRS stock under the Base Case scenario is 32.08 USD. Compared to the current market price of 11.94 USD, Viatris Inc is Undervalued by 63%.
Valuation Backtest
Viatris Inc
Run backtest to discover the historical profit from buying and selling VTRS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Viatris Inc's business.
What risks and challenges
does Viatris Inc face in the near future?
Summarize the latest earnings report
of Viatris Inc.
Provide P/E
for Viatris Inc and its competitors.
Balance Sheet Decomposition
Viatris Inc
Current Assets | 13B |
Cash & Short-Term Investments | 1.1B |
Receivables | 3.7B |
Other Current Assets | 8.2B |
Non-Current Assets | 34.7B |
Long-Term Investments | 165.7m |
PP&E | 3B |
Intangibles | 29B |
Other Non-Current Assets | 2.5B |
Current Liabilities | 7.8B |
Accounts Payable | 1.4B |
Accrued Liabilities | 2.3B |
Other Current Liabilities | 4.1B |
Non-Current Liabilities | 19.4B |
Long-Term Debt | 16.2B |
Other Non-Current Liabilities | 3.3B |
Earnings Waterfall
Viatris Inc
Revenue
|
15.4B
USD
|
Cost of Revenue
|
-8.7B
USD
|
Gross Profit
|
6.7B
USD
|
Operating Expenses
|
-5.1B
USD
|
Operating Income
|
1.6B
USD
|
Other Expenses
|
-1.5B
USD
|
Net Income
|
54.7m
USD
|
Free Cash Flow Analysis
Viatris Inc
What is Free Cash Flow?
VTRS Profitability Score
Profitability Due Diligence
Viatris Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Viatris Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
VTRS Solvency Score
Solvency Due Diligence
Viatris Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Viatris Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VTRS Price Targets Summary
Viatris Inc
According to Wall Street analysts, the average 1-year price target for VTRS is 12.09 USD with a low forecast of 10.1 USD and a high forecast of 14.7 USD.
Ownership
VTRS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VTRS Price
Viatris Inc
Average Annual Return | -18.87% |
Standard Deviation of Annual Returns | 7.2% |
Max Drawdown | -69% |
Market Capitalization | 14.3B USD |
Shares Outstanding | 1 187 570 000 |
Percentage of Shares Shorted | 4.11% |
VTRS News
Last Important Events
Viatris Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Viatris Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. The company is headquartered in Canonsburg, Pennsylvania and currently employs 37,000 full-time employees. The firm has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. The company operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Contact
IPO
Employees
Officers
The intrinsic value of one VTRS stock under the Base Case scenario is 32.08 USD.
Compared to the current market price of 11.94 USD, Viatris Inc is Undervalued by 63%.